BFEC
AMRX icon

Benjamin F. Edwards & Company’s Amneal Pharmaceuticals AMRX Stock Holding History

Benjamin F. Edwards & Company’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-48
Closed – – 1827
2019
Q2 		$0 Buy
+48
New +$491 ﹤0.01% 1899

Other funds holding AMRX

FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Benjamin F. Edwards & Company's AMRX Position: Q3 2019 in Review

Benjamin F. Edwards & Company sold out of Amneal Pharmaceuticals (AMRX) in Q3 2019, closing a stake of 48 shares.

Benjamin F. Edwards & Company first reported a position in AMRX in Q2 2019 and held it in 1 quarter. The position peaked at $0 in Q2 2019. 121 funds tracked by Wall St. Rank hold AMRX as of Q3 2019.

  • Benjamin F. Edwards & Company reported no remaining Amneal Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Benjamin F. Edwards & Company sold 48 Amneal Pharmaceuticals shares in Q3 2019.
  • Benjamin F. Edwards & Company first reported a position in Amneal Pharmaceuticals in Q2 2019 and held it in 1 quarter.
  • Benjamin F. Edwards & Company's Amneal Pharmaceuticals position peaked at $0 in Q2 2019.
  • 121 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2019.

Based on Benjamin F. Edwards & Company's 13F filing for Q3 2019, filed 5 Nov 2019.